Design and Development of a Series of Potent and Selective Type II Inhibitors 
of CDK8

Bergeron, Philippe; Koehler, Michael F. T.; Blackwood, Elizabeth M.; Bowman, Krista; Clark, Kevin; Firestein, Ron; Kiefer, James R.; Maskos, Klaus; McCleland, Mark L.; Orren, Linda; Ramaswamy, Sreemathy; Salphati, Laurent; Schmidt, Steve; Schneider, Elisabeth V.; Wu, Jiansheng; Beresini, Maureen

doi:10.1021/acsmedchemlett.6b00044

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

Design and Development of a Series of Potent and Selective Type II Inhibitors of CDK8

MPS-Authors

/persons/resource/persons78652

Schneider, Elisabeth V.
Huber, Robert / Structure Research, Max Planck Institute of Biochemistry, Max Planck Society;

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Bergeron, P., Koehler, M. F. T., Blackwood, E. M., Bowman, K., Clark, K., Firestein, R., et al. (2016). Design and Development of a Series of Potent and Selective Type II Inhibitors of CDK8. ACS Medicinal Chemistry Letters, 7(6), 595-600. doi:10.1021/acsmedchemlett.6b00044.

Cite as: https://hdl.handle.net/11858/00-001M-0000-002B-00F9-F

Abstract

Using Sorafenib as a starting point, a series of potent and selective inhibitors of CDK8 was developed. When cocrystallized with CDK8 and cyclin C, these compounds exhibit a Type-II (DMG-out) binding mode.